惠民福利国产成人97精品免费看片_日韩视频一区二区12p_国产又色又爽又黄在线观看视频_最新国产vr麻豆aⅴ精品无_肉丝超薄丝袜交一区二区_好色先生tv免费视频_免费高清在线蜜乳AV_破外女出血在线视频_高清欧美精品亚洲_手机看片福利永久片你


管理培訓(xùn)搜索
18318889481 13681114876

合規(guī)
| 美國(guó)最高法院拒絕澄清虛假索賠法的虛假標(biāo)準(zhǔn)當(dāng)前您所在的位置:首頁(yè) > 合規(guī) > 反洗錢中心 > 舞弊新聞

U.S. Supreme Court Declines to Clarify False Claims Act Falsity Standard

        The U.S. Supreme Court recently declined to address a circuit split regarding the standard for establishing that a statement material to a claim for payment is false under the False Claims Act (FCA); specifically, whether the FCA requires pleading and proof of an “objectively false statement,” or whether liability can be based on allegedly false opinions. While the Courts of Appeals have taken conflicting positions on these issues, the circuit split is not as deep as would appear and the variation in standards are likely to have a minimal impact on ultimate outcomes. Nevertheless, with these varying standards for establishing falsity, healthcare providers and government contractors should take proactive steps to ensure signed certifications pertinent to a claim reflect appropriate diligence and decision-making and convey reasonably and honestly held opinions.

 

        A plaintiff must allege and prove the following to prevail on an FCA claim: (1) a false statement, (2) made with the requisite scienter (or knowledge that it was false), (3) that was material, causing (4) the government to pay out money. The threshold issue here relates to the proof required to establish the first prong, that information in or material to a claim is actually false. Assessing whether an opinion conveyed in a relevant certification is reasonably held or is false, however, is inextricably tied to the assessment of the second element, whether the statement was made with the requisite knowledge of the fraudulent nature of the statement (and either deliberate ignorance or reckless indifference is sufficient to establish scienter in the FCA context).

 

        On February 22, 2021, the U.S. Supreme Court denied petitions for certiorari in two cases seeking review of opinions of the Third and Ninth Circuits in United States ex rel. Druding v. Care Alternatives, 952 F.3d 89, 97 (3d Cir. 2020), and United States ex rel. Winter v. Gardens Regional Hospital and Medical Center, 953 F.3d 1108, 1114 (9th Cir. 2020), respectively, regarding whether the FCA required proof of an “objective falsity” in a material statement to establish liability. Both cases involve allegations of healthcare fraud arising from false physician certifications, and the circuit opinions in those cases both address the “objective false statement” standard articulated by the Eleventh Circuit in United States v. AseraCare, Inc., 938 F.3d 1278 (11th Cir. 2019).

 

        In the AseraCare case, which involved allegations centering on purportedly false certifications that federal healthcare program beneficiaries were terminally ill and therefore eligible for hospice services, the Eleventh Circuit held that to properly state a claim under the FCA, the plaintiff must demonstrate an objective falsity in the statement at issue, which is “something more than the mere difference of reasonable opinion.”

 

        In contrast, the Third Circuit in ex rel. Druding (another case centering on allegedly false terminal illness certifications) flatly rejected the AseraCare Court’s objective falsity standard for FCA claims. The Third Circuit reasoned that “clinical judgments” like other opinions, can “be ‘false’ for purposes of FCA liability.” The Care Alternatives Court further held that the objective falsity standard “improperly conflates the elements of scienter and falsity,” effectively reading the scienter requirement out of the statute: “objectivity speaks to the element of scienter, not falsity … the text and application of the FCA require that the elements of falsity and scienter be analyzed separately.”

 

        Similarly, the Ninth Circuit in ex rel. Winter (involving allegedly false certifications that hospitalization was medically necessary for federal healthcare program beneficiaries) rejected the argument “that only ‘objectively false’ statements can give rise to FCA liability.” The court noted that, “under the common law, a subjective opinion is fraudulent if it implies the existence of facts that do not exist or if it is not honestly held.” Despite concluding that a physician’s opinion with “no basis in fact can be fraudulent if expressed with scienter,” the Ninth Circuit claimed that their decision did not conflict with AseraCare. The Winter Court reasoned that the AseraCare objective falsity standard was limited to the fact specific and inherently speculative context of the “hospice-benefit provision at issue” (i.e., the forward-looking assessment that a patient was terminally ill and so likely had six months or less to live).

 

        With the Supreme Court declining to provide clarity, government contractors, healthcare entities, and other heavily regulated industries should take note of the ongoing legal uncertainty and potentially disparate levels of risk in different parts of the country. It is unclear to what extent, if any, that entities can rely on AseraCare and the objective falsity standard outside of the Eleventh Circuit (Alabama, Florida, and Georgia) and the hospice context.

 

        That said, the careful reading of the three circuit opinions shows that there is less to the circuit split than meets the eye: While the Eleventh Circuit did adopt an “objective falsity” standard that the Third and Ninth Circuits rejected, the AseraCare Court took pains to broadly define “objective falsity” to include not only patently false certifications containing forged or “rubber stamped” signatures, but also opinions that are not honestly held or reasonable. As such, even the Eleventh Circuit conceded that statements of opinion and clinical judgment can be false if they “disregard[] the patient’s underlying medical condition” and so are not necessarily immune from liability. Moreover, while the AseraCare Court held that a certifying physician’s state of mind must be considered when assessing falsity, and the Ninth and Third Circuits held that such an analysis should be conducted when evaluating scienter, the elements of falsity and knowledge are tightly intertwined: Whether an opinion was dishonestly or unreasonably held (and therefore false), and whether that opinion was conveyed with the knowledge that is was false, are closely related questions. That being the case, whether state of mind is assessed in determining both falsity and scienter, or just scienter, is not likely to affect the outcome of most cases.

 

        Companies should be conscious that a certifying official’s opinion may trigger FCA liability if it is not supported by evidence or if it is not reasonably or honestly held. The fact that a statement at issue may be an opinion or an expression of professional judgment will not automatically immunize the statement from liability, no matter which circuit the case is in. Healthcare providers and government contractors should therefore consider reviewing internal policies related to certifications that are material to a claim for payment. Companies are encouraged to be proactive in mitigating the risk of enforcement actions, including through the maintenance of a robust Governance, Risk, and Compliance (GRC) program and periodic audits of business processes to ensure certifications are supported by documentation in the clinical records or contract files, and made in an environment conducive to considered judgment and free from inappropriate pressure. These proactive mitigating steps are especially important where noncompliance includes the potential for treble damages and per invoice penalties under the FCA.

來(lái)源:ACFE官網(wǎng) 

TESG
企業(yè)概況
聯(lián)系我們
專家顧問(wèn)
企業(yè)文化
黨風(fēng)建設(shè)
核心團(tuán)隊(duì)
資質(zhì)榮譽(yù)
合規(guī)監(jiān)管
部門職責(zé)
轉(zhuǎn)創(chuàng)中國(guó)
加入轉(zhuǎn)創(chuàng)
經(jīng)濟(jì)合作
智庫(kù)專家
質(zhì)量保證
咨詢流程
聯(lián)系我們
咨詢
IPO咨詢
投融資咨詢
會(huì)計(jì)服務(wù)
績(jī)效管理
審計(jì)和風(fēng)險(xiǎn)控制
競(jìng)爭(zhēng)戰(zhàn)略
審計(jì)與鑒證、估價(jià)
企業(yè)管理咨詢
人力資源戰(zhàn)略與規(guī)劃
融資與并購(gòu)財(cái)務(wù)顧問(wèn)服務(wù)
投資銀行
企業(yè)文化建設(shè)
財(cái)務(wù)交易咨詢
資本市場(chǎng)及會(huì)計(jì)咨詢服務(wù)
創(chuàng)業(yè)與私營(yíng)企業(yè)服務(wù)
公司治理、合規(guī)與反舞弊
國(guó)企改革
價(jià)值辦公室
集團(tuán)管控
家族企業(yè)管理
服務(wù)
數(shù)據(jù)分析
資信評(píng)估
投資咨詢
風(fēng)險(xiǎn)及控制服務(wù)
管理咨詢
轉(zhuǎn)型升級(jí)服務(wù)
可行性研究咨詢服務(wù)
民企與私人客戶服務(wù)
解決方案
內(nèi)控
稅收內(nèi)部控制
稅收風(fēng)險(xiǎn)管理
內(nèi)控管理師
內(nèi)部控制咨詢
信用研究
信用法制中心
風(fēng)險(xiǎn)與內(nèi)控咨詢
無(wú)形資產(chǎn)內(nèi)控
企業(yè)內(nèi)控審計(jì)
內(nèi)部控制服務(wù)
內(nèi)部控制評(píng)價(jià)
內(nèi)部控制體系建設(shè)
內(nèi)部控制智庫(kù)
上市公司內(nèi)控
上市公司獨(dú)立董事
投行
M&A
資本市場(chǎng)
SPAC
科創(chuàng)板
金融信息庫(kù)
IPO咨詢
北交所
ASX
SGX
HKEX
金融服務(wù)咨詢
信用評(píng)級(jí)
上海證券交易所
NYSE
深圳證券交易所
審計(jì)
審計(jì)資料下載
法證會(huì)計(jì)
審計(jì)事務(wù)
審計(jì)及鑒證服務(wù)
審計(jì)咨詢
反舞弊中心
內(nèi)部控制審計(jì)
內(nèi)部審計(jì)咨詢
國(guó)際審計(jì)
合規(guī)
銀行合規(guī)專題
合規(guī)管理建設(shè)年
海關(guān)與全球貿(mào)易合規(guī)
數(shù)據(jù)合規(guī)專題
反腐敗中心
反壟斷合規(guī)
反舞弊中心
國(guó)際制裁
企業(yè)合規(guī)中心
信用合規(guī)專題
證券合規(guī)專題
合規(guī)中心
金融合規(guī)服務(wù)
反洗錢中心
全球金融犯罪評(píng)論
行業(yè)
新基建
文化、體育和娛樂(lè)業(yè)
電信、媒體和技術(shù)(TMT)
投城交通事業(yè)部
房地產(chǎn)建筑工程
醫(yī)療衛(wèi)生和社會(huì)服務(wù)
可持續(xù)發(fā)展與環(huán)保
全球基礎(chǔ)材料
大消費(fèi)事業(yè)部
金融服務(wù)業(yè)
化學(xué)工程與工業(yè)
一帶一路
智慧生活與消費(fèi)物聯(lián)
數(shù)字經(jīng)濟(jì)發(fā)展與檢測(cè)
食品開(kāi)發(fā)與營(yíng)養(yǎng)
先進(jìn)制造事業(yè)部
能源資源與電力
消費(fèi)與工業(yè)產(chǎn)品
運(yùn)輸與物流
酒店旅游餐飲
科學(xué)研究與技術(shù)服務(wù)
政府及公共事務(wù)
化妝品與個(gè)人護(hù)理
一二三產(chǎn)融合
生物醫(yī)藥與大健康
新能源汽車與安全產(chǎn)業(yè)
法律
法律信息庫(kù)
稅法與涉稅服務(wù)
數(shù)字法治與網(wǎng)絡(luò)安全
勞動(dòng)與人力資源法律
金融與資本市場(chǎng)法律
司法研究所
公司法專題
私募股權(quán)與投資基金
債務(wù)重組與清算/破產(chǎn)
轉(zhuǎn)創(chuàng)國(guó)際法律事務(wù)所
轉(zhuǎn)創(chuàng)法信事務(wù)所
財(cái)稅
法務(wù)會(huì)計(jì)
管理會(huì)計(jì)案例
決策的財(cái)務(wù)支持
家族資產(chǎn)和財(cái)富傳承
財(cái)稅法案例庫(kù)
資產(chǎn)評(píng)估
財(cái)稅信息庫(kù)
會(huì)計(jì)準(zhǔn)則
財(cái)務(wù)研究所
財(cái)政稅收
財(cái)政研究所
會(huì)計(jì)研究所
財(cái)稅實(shí)務(wù)
投資咨詢
財(cái)務(wù)管理咨詢
審計(jì)事務(wù)
管理
轉(zhuǎn)創(chuàng)智庫(kù)
金融研究所
企業(yè)管理研究所
中國(guó)企業(yè)國(guó)際化發(fā)展
經(jīng)濟(jì)與產(chǎn)業(yè)研究
氣候變化與可持續(xù)
ESG中心
管理咨詢
轉(zhuǎn)創(chuàng)
咨詢業(yè)數(shù)據(jù)庫(kù)
轉(zhuǎn)創(chuàng)網(wǎng)校
生物醫(yī)藥信息庫(kù)
建筑工程庫(kù)
轉(zhuǎn)創(chuàng)首都
轉(zhuǎn)創(chuàng)教育
轉(zhuǎn)創(chuàng)國(guó)際廣東 官網(wǎng)
科研創(chuàng)服
中國(guó)轉(zhuǎn)創(chuàng)雜志社
創(chuàng)新創(chuàng)業(yè)
轉(zhuǎn)型升級(jí)
技術(shù)轉(zhuǎn)移中心
轉(zhuǎn)創(chuàng)中國(guó)
中外
粵港澳大灣區(qū)
中國(guó)-東盟
一帶一路
澳大利亞
俄羅斯
新加坡
英國(guó)
加拿大
新西蘭
香港
美國(guó)
中非平臺(tái)
開(kāi)曼群島
法國(guó)
歐洲聯(lián)盟
印度
北美洲
18318889481 13681114876
在線QQ
在線留言
返回首頁(yè)
返回頂部
留言板
發(fā)送